NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD

NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD (China) holds 9 active US FDA Type II Drug Master Files and has DMF or CEP filings on record for 1 active ingredient. No FDA recall, Warning Letter or Form 483 record is linked to it, which is not proof that none exists.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/nantong-noatic-bio-pharm-technology-co-ltd

Overview

NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD is an active pharmaceutical ingredient (API) supplier with 6 active FDA Type II Drug Master Files, covering (2R,3R)-3-(2,5-DIFLUOROPHENYL)-3-HYDROXY-2-METHYL-4-(1H-1,2,4-TRIAZOL-1-YL) THIOBUTYRAMIDE; LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LP-4; LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPA; LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPB; LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPE-5; SEMAGLUTIDE DRUG SUBSTANCE INTERMEDIATE XSC.

Core services & business areas

API Manufacturing

Active ingredients with DMF or CEP filings

Substances for which NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD holds 9 active (9 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • ORFORGLIPRON DRUG SUBSTANCE INTERMEDIATE OGEActive2026-09-09
  • LENACAPAVIR SODIUM DRUG SUBSTANCEActive2026-07-29
  • ORFORGLIPRON DRUG SUBSTANCE INTERMEDIATE OGHActive2026-04-29
  • SEMAGLUTIDE DRUG SUBSTANCE INTERMEDIATE XSCActive2026-01-14
  • LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LP-4Active2025-11-06
  • LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPE-5Active2025-10-17
  • LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPAActive2025-09-22
  • LENACAPAVIR DRUG SUBSTANCE INTERMEDIATE LPBActive2025-09-22
  • (2R,3R)-3-(2,5-DIFLUOROPHENYL)-3-HYDROXY-2-METHYL-4-(1H-1,2,4-TRIAZOL-1-YL) THIOBUTYRAMIDEActive2024-11-11

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.

For suppliers

Is this NANTONG NOATIC BIO-PHARM TECHNOLOGY CO LTD?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.